Slingshot members are tracking this event:

Novartis (NVS) late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
The aim of psoriasis treatment is clear skin, and the Psoriasis Area Severity Index (PASI) 90 response is considered an important measure of treatment success[3]-[6]. Clear or almost clear skin (PASI 90) was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4 (66.4%)[1]. In addition, 43.8% of psoriasis patients achieved completely clear skin (PASI 100) at Year 1 and this rate (43.5%) was maintained to Year 4. The average improvement of psoriasis as measured by the PASI score was maintained at over 90% after 4 years of treatment*. The standard goal of treatment, PASI 75 response, was achieved by 88.5% of patients at Year 4. In this long-term study, Cosentyx continues to have a favorable safety profile, which was consistent with that demonstrated in previous Phase III studies.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 01, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Skin Clearance, Psoriasis Patients, Cosentyx, Pasi 75